304 related articles for article (PubMed ID: 3263702)
21. Alterations in EGF-dependent proliferative and phosphorylation events in squamous cell carcinoma cell lines by a tyrosine kinase inhibitor.
Brunton VG; Carlin S; Workman P
Anticancer Drug Des; 1994 Aug; 9(4):311-29. PubMed ID: 7916899
[TBL] [Abstract][Full Text] [Related]
22. Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns.
Wosikowski K; Schuurhuis D; Johnson K; Paull KD; Myers TG; Weinstein JN; Bates SE
J Natl Cancer Inst; 1997 Oct; 89(20):1505-15. PubMed ID: 9337347
[TBL] [Abstract][Full Text] [Related]
23. Clavilactones, a novel class of tyrosine kinase inhibitors of fungal origin.
Cassinelli G; Lanzi C; Pensa T; Gambetta RA; Nasini G; Cuccuru G; Cassinis M; Pratesi G; Polizzi D; Tortoreto M; Zunino F
Biochem Pharmacol; 2000 Jun; 59(12):1539-47. PubMed ID: 10799650
[TBL] [Abstract][Full Text] [Related]
24. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor-induced apoptosis in A431 cells can be reversed by reducing the tyrosine kinase activity.
Gulli LF; Palmer KC; Chen YQ; Reddy KB
Cell Growth Differ; 1996 Feb; 7(2):173-8. PubMed ID: 8822200
[TBL] [Abstract][Full Text] [Related]
26. Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors.
Geissler JF; Traxler P; Regenass U; Murray BJ; Roesel JL; Meyer T; McGlynn E; Storni A; Lydon NB
J Biol Chem; 1990 Dec; 265(36):22255-61. PubMed ID: 2176210
[TBL] [Abstract][Full Text] [Related]
27. A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo.
Lydon NB; Mett H; Mueller M; Becker M; Cozens RM; Stover D; Daniels D; Traxler P; Buchdunger E
Int J Cancer; 1998 Mar; 76(1):154-63. PubMed ID: 9533776
[TBL] [Abstract][Full Text] [Related]
28. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
29. P2Y receptor-mediated stimulation of Müller glial cell DNA synthesis: dependence on EGF and PDGF receptor transactivation.
Milenkovic I; Weick M; Wiedemann P; Reichenbach A; Bringmann A
Invest Ophthalmol Vis Sci; 2003 Mar; 44(3):1211-20. PubMed ID: 12601051
[TBL] [Abstract][Full Text] [Related]
30. Analogs of human epidermal growth factor which partially inhibit the growth factor-dependent protein-tyrosine kinase activity of the epidermal growth factor receptor.
Matsunami RK; Campion SR; Niyogi SK; Stevens A
FEBS Lett; 1990 May; 264(1):105-8. PubMed ID: 2159890
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor.
Reddy KB; Mangold GL; Tandon AK; Yoneda T; Mundy GR; Zilberstein A; Osborne CK
Cancer Res; 1992 Jul; 52(13):3636-41. PubMed ID: 1617636
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of the EGF-stimulated cellular proliferation of ER 22 cells by hydroxybiphenyl derivatives.
Million ME; Boiziau J; Parker F; Tocque B; Roques BP; Garbay C
J Med Chem; 1995 Nov; 38(23):4693-703. PubMed ID: 7473597
[TBL] [Abstract][Full Text] [Related]
33. Intermolecular transphosphorylation between insulin receptors and EGF-insulin receptor chimerae.
Ballotti R; Lammers R; Scimeca JC; Dull T; Schlessinger J; Ullrich A; Van Obberghen E
EMBO J; 1989 Nov; 8(11):3303-9. PubMed ID: 2583100
[TBL] [Abstract][Full Text] [Related]
34. Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor.
Huang YT; Hwang JJ; Lee PP; Ke FC; Huang JH; Huang CJ; Kandaswami C; Middleton E; Lee MT
Br J Pharmacol; 1999 Nov; 128(5):999-1010. PubMed ID: 10556937
[TBL] [Abstract][Full Text] [Related]
35. Suppression of extracellular signals and cell proliferation by the black tea polyphenol, theaflavin-3,3'-digallate.
Liang YC; Chen YC; Lin YL; Lin-Shiau SY; Ho CT; Lin JK
Carcinogenesis; 1999 Apr; 20(4):733-6. PubMed ID: 10223207
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor-specific protein tyrosine phosphorylation in preimplantation embryo development.
Paria BC; Tsukamura H; Dey SK
Biol Reprod; 1991 Nov; 45(5):711-8. PubMed ID: 1721842
[TBL] [Abstract][Full Text] [Related]
37. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Regenass U; Lydon NB
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2558-62. PubMed ID: 7708684
[TBL] [Abstract][Full Text] [Related]
38. Lidocaine inhibits tyrosine kinase activity of the epidermal growth factor receptor and suppresses proliferation of corneal epithelial cells.
Hirata M; Sakaguchi M; Mochida C; Sotozono C; Kageyama K; Kuroda Y; Hirose M
Anesthesiology; 2004 May; 100(5):1206-10. PubMed ID: 15114219
[TBL] [Abstract][Full Text] [Related]
39. A431 cell variants lacking the blood group A antigen display increased high affinity epidermal growth factor-receptor number, protein-tyrosine kinase activity, and receptor turnover.
Defize LH; Arndt-Jovin DJ; Jovin TM; Boonstra J; Meisenhelder J; Hunter T; de Hey HT; de Laat SW
J Cell Biol; 1988 Sep; 107(3):939-49. PubMed ID: 2458364
[TBL] [Abstract][Full Text] [Related]
40. BE-23372M, a novel and specific inhibitor for epidermal growth factor receptor kinase.
Tanaka S; Okabe T; Chieda S; Endo K; Kanoh T; Okura A; Yoshida E
Jpn J Cancer Res; 1994 Mar; 85(3):253-9. PubMed ID: 8188523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
